Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-025791
Filing Date
2021-05-10
Accepted
2021-05-10 08:33:44
Documents
54
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q agle-10q_20210331.htm   iXBRL 10-Q 2249662
2 EX-10.1 agle-ex101_317.htm EX-10.1 663924
3 EX-31.1 agle-ex311_6.htm EX-31.1 15957
4 EX-32.1 agle-ex321_8.htm EX-32.1 7079
  Complete submission text file 0001564590-21-025791.txt   7435679

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA agle-20210331.xsd EX-101.SCH 39900
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE agle-20210331_cal.xml EX-101.CAL 43365
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE agle-20210331_def.xml EX-101.DEF 110010
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20210331_lab.xml EX-101.LAB 311498
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20210331_pre.xml EX-101.PRE 226103
10 EXTRACTED XBRL INSTANCE DOCUMENT agle-10q_20210331_htm.xml XML 1163503
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37722 | Film No.: 21905375
SIC: 2834 Pharmaceutical Preparations